RoosterBio Expands Executive Leadership Team for Future Growth
VP of Operations, General Counsel and Director of HR Appointed
FREDERICK, Md. (Original Release Via PRWEB) March 08, 2019
On the heels of an expansion of its innovative regenerative medicine technology products, RoosterBio, Inc, a privately held company, has announced the recent additions of Sheli Streck, Ed Radwinsky and Mary E. Fletcher. Sheli Streck serves as the Vice President of Operations, Mary Fletcher is RoosterBio’s General Counsel and Ed Radwinsky is Human Resources Director. All positions report directly to Margot Connor, RoosterBio’s Chief Executive Officer.
“We are very proud to have built a first-class leadership team at RoosterBio as we continue to evolve rapidly at every level,” said CEO Margot S. Connor. “These strong additions, along with an expansion of our facility will further enhance our capabilities and facilitate company growth.”
Sheli Streck, VP of Commercial Operations for RoosterBio, brings 20 years of diversified pharma and biotech experience which includes management of several global sales teams, international distributors and other supporting functions necessary to grow sales revenue. Streck leads the company’s growing commercial team.
Mary E. Fletcher has been appointed General Counsel, bringing a collective 25 plus years of diverse legal experience in both private practice and in-house experience. Prior to joining RoosterBio, she was a partner of Fletcher & Fletcher, PC, a general practice and real estate law firm where she focused her efforts on assisting clients in general corporate, commercial, transactional and governance matters.
Ed Radwinsky has more than 20 years of experience in human resources including the last 14 years in biotech field where he regularly advised senior leaders on both strategic and tactical matters regarding the delivery of core human resources initiatives. Radwinsky is charged with leading RoosterBio’s human resources efforts.
Headquartered in Frederick, MD and serving customers in 18 countries, the company is continuing to hire. Qualified candidates with a strong desire to help define the industry can visit RoosterBio’s Career page for available opportunities.
About RoosterBio, Inc.
RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable regenerative medicine industry, one customer at a time. RoosterBio’s products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, accelerating the road to discovery in Regenerative Medicine. For more information on RoosterBio, please visit http://www.roosterbio.com.
Latest posts by Chris Frew (see all)
- Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study - November 2, 2021
- Children’s National’s Dr. Kurt Newman Named WBJ’s 2021 CEO of the Year - October 26, 2021
- SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases | Business Wire - October 26, 2021
- Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire - October 21, 2021
- D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases - October 19, 2021